Actuate Therapeutics Inc
ACTU · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | -0.03 | -0.23 | 0.00 |
| FCF Yield | -32.77% | -16.71% | -13.75% |
| EV / EBITDA | -2.32 | -5.18 | -5.43 |
| Quality | |||
| ROIC | -4,876.77% | 636.27% | -125.21% |
| Gross Margin | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.87 | 0.88 |
| Growth | |||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -1.01% | -21.53% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 0.33 | 0.12 | 1.02 |
| Interest Coverage | 1,344.27 | -572.26 | -1,247.33 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 |